Mosanna Therapeutics AG closed an extension of the Seed Financing Round with Supermoon Capital and High-Tech Gründerfonds

Mosanna Therapeutics AG, a Basel-based biotechnology company developing the highly differentiated small molecule MOS118 for the treatment of metabolic obstructive sleep apnea, closes an extension of the Seed Financing Round with the investors Supermoon Capital and High-Tech Gründerfonds (HTGF). These investors join the Seed Financing Round with the existing lead investor Forty51 Ventures.

The VISCHER team includes Matthias Staehelin (Partner), Timothy Woodtli (Associate) and Christoph Enz (Associate) (all Corporate/M&A).

Matthias Staehelin

Attorney at Law and Civil Law Notary (BS/BL)

• Partner

• +41 58 211 33 53
• [email protected]

Timothy Woodtli

Attorney at Law

• Senior Associate

• +41 58 211 32 20
• [email protected]

Christoph A. Enz

Attorney at Law, Civil Law Notary (BS/BL)

• Associate

• +41 58 211 32 30
• [email protected]